Latest Fractyl Health News & Updates

See the latest news and media coverage for Fractyl. We track all announcements, press releases, and industry mentions in real time, all in one place.

Fractyl Health (Fractyl)

Developer of metabolic therapies for obesity and type 2 diabetes

fractyl.com

Headquarters: Burlington, United States
Founded year: 2010
Company type: Public company
Number of employees: 100–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Fractyl Health (Fractyl)

In short: Fractyl Health advanced its metabolic pipeline with positive Revita weight maintenance data and the launch of a first-in-human gene trial.

Company announcements

July 15 Fractyl

Fractyl reports positive randomized data for weight maintenance after GLP-1 discontinuation

Revita maintained 84% of weight loss vs 46% with sham at one year in optimized cohort.

June 4 Fractyl

Fractyl reports positive one-year Revita weight maintenance results

Patients retained ~78% of GLP-1-induced weight loss after a single procedure; 33% continued losing weight.

May 11 Fractyl

Fractyl Health initiates first-in-human RJVA-001 trial

The Netherlands authorized a Phase 1/2 study of RJVA-001, the first AAV gene therapy for type 2 diabetes, with dosing and preliminary data expected in H2 2026.

April 27 Fractyl

Fractyl Health highlights REMAIN-1 trial results

Results show reduced weight regain after GLP-1 discontinuation using Revita®. Dr. Sullivan presents six-month data at DDW2026 on May 4th.

Media coverage

July 15 Markets Insider

Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation

Up to 84% of GLP-1 induced weight loss retained with Revita® versus 46% with shamat one year in patients receiving complete duodenal...

July 11 Yahoo Finance

Fractyl Health (GUTS) Stock Sees Fair Value Cut As Analysts Weigh Revita Opportunity

Fractyl Health is under fresh scrutiny after analysts reset its fair value estimate from US$7.44 to US$5.03 per share, a shift that reframes expectations around...

June 26 The Globe and Mail

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Detailed price information for Fractyl Health Inc (GUTS-Q) from The Globe and Mail including charting and trades.

June 12 Yahoo Finance

Fractyl Health Inc (GUTS) Cleared for RJVA-001 Trial. Let's Look At Funding

Fractyl Health Inc (NASDAQ:GUTS) is one of billionaire Lee Ainslie's stocks with huge upside potential. The stock has gained roughly 18% over the past month...

Never miss news about Fractyl

Track Fractyl and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Fractyl competitors & trending companies

Browse news for competitors to Fractyl and other trending companies.